Navigation Links
PET predicts outcomes for patients with cervical spinal cord compression
Date:9/4/2013

Reston, Va. (September 4, 2013) For patients with degenerative cervical myelopathy, imaging with 18F-FDG positron emission tomography (PET) could act as a marker for a potentially reversible phase of the disease in which substantial clinical improvement can be achieved. According to research published in the September issue of The Journal of Nuclear Medicine, patients who exhibited hypermetabolism at the point of compression in their spine experienced improved outcomes after undergoing decompressive surgery.

Cervical spinal stenosis is a condition in which the spinal canal narrows in the neck. While many patients lack symptoms, once symptoms appear, it usually indicates the presence of myelopathy. This compression can lead to progressive neurologic deficits, such as numbness, weakness or tingling in a leg, foot, arm or hand.

In the study "Hypermetabolism in 18F-FDG PET Predicts Favorable Outcome Following Decompressive Surgery in Patients with Degenerative Cervical Myelopathy," researchers aimed to assess the regional changes of glucose metabolism of the cervical spinal cord using 18F-FDG PET. "To date, experiences with 18F-FDG PET in symptomatic patients with degenerative cervical spine stenosis and consecutive compressive myelopathy are very limited," said Norbert Galldiks, MD, one of the lead researchers of the study. "In the present study, we present the results of preoperative magnetic resoncance imaging and 18F-FDG PET imaging and postoperative follow-up imaging 12 months after decompressive surgery. Imaging findings were correlated with the clinical outcome."

Researchers observed two significantly different patterns of 18F-FDG uptake among the 20 study participants prior to surgeryapproximately half of the patients had increased 18F-FDG uptake at the site of spinal cord compression and were classified as myelopathy type 1, while the other half had inconspicuous 18F-FDG uptake and were classified as myelopathy type 2. Post-operatively, those with myelopathy type 1 had a marked decrease in 18F-FDG uptake, while myelopathy type 2 patients had only a moderate decline in uptake.

The overall outcome in myelopathy type 1 patients was favorable, and the patients showed significant improvement on their functional status assessment. In contrast, there was no significant clinical change in patients with inconspicuous 18F-FDG uptake.

"A hypermetabolism of the cervical spinal cord at the level of cervical spine stenosis as indicated by a locally increased 18F-FDG uptake seems to be a marker for a potentially reversible phase of a compression-induced cervical myelopathy," explained Galldiks. "The lesion of the spinal cord seems to be predominantly functional. Presence of this metabolic pattern reflects the time frame when decompressive surgery can lead to substantial clinical improvement. In order to stratify eligible patients for decompressive surgery, our findings may help to implement 18F-FDG PET investigations of the cervical spine in clinical routine."


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Protein-based urine test predicts kidney transplant outcomes
2. Low childhood conscientiousness predicts adult obesity
3. Novus Medical Detox Predicts Taxpayer-Paid Drug Abuse Amid Medicare Fraud, Urges Federal Regulations
4. Study predicts potential surge in medically-attended injuries
5. Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment
6. The Tourism Authority of Thailand Predicts 1.42 Million Japanese Visitors in 2013 Following This Year’s Thai Tourism Festival in Tokyo
7. A statistical model predicts the number of goals for each footballer
8. Simple frailty test predicts death, hospitalization for kidney dialysis patients
9. Genetic diversity within tumors predicts outcome in head and neck cancer
10. Study shows that bedtime regularity predicts CPAP compliance
11. Warning system predicts outbreaks of dengue fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: